News | December 28, 2016

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmacopeia (USP) recommendations for compounded sterile radiopharmaceuticals. The recommendations aim to address certain common practices in the field of nuclear pharmacy that are not adequately defined by generally accepted practice standards. The society believes there is confusion in the field of nuclear pharmacy, which threatens the availability and the safe usage of radiopharmaceuticals in the United States. The recommendations are a response to these challenges. 

The recommendations were developed by SNMMI's Committee on Radiopharmaceuticals (COR) and approved by SNMMI's Board of Directors. The COR worked with several professional organizations and trade associations in an attempt to rectify the situation. Our efforts to date have met with some success, but have still fallen short of realizing suitable standards that are generally accepted for common practices in nuclear pharmacy. The COR believes that the USP, as the world’s leading organization for the development and maintenance of public standards, can play a critical role in the resolution of these challenges. 

There are three recommendations detailed in a SNMMI white paper: 

1. Establish an expert panel to delineate common practices that are defined as sterile compounding within the practice of nuclear pharmacy.
2. Create a public standard for the preparation, compounding, and dispensing of sterile radiopharmaceuticals with the practice of nuclear pharmacy.
3. Reinstate an expert committee dedicated to all standards for radiopharmaceuticals.

On September 29, SNMMI President Sally Schwarz sent the letter to the USP, where it is currently under consideration. Further details will be provided as they become available.

Access the complete document at http://snmmi.files.cms-plus.com/SNMMI-USP-Recommendations-Final_2016.pdf

Related Content

stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Neuro Imaging | January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
News | Radiopharmaceuticals and Tracers | January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017
Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category...
prostate, CT scan
News | Prostate Cancer | December 22, 2016
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and...
News | Prostate Cancer | December 14, 2016
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that...
News | Nuclear Imaging | December 12, 2016
Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected...
Numa, NumaStatus, radiation dose reporting software, RSNA 2016
News | Radiation Dose Management | December 08, 2016
Numa introduced a new software application at the 2016 Annual Meeting of the Radiological Society of North America (...
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia. 

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
xSPECT Quant technology, SPECT/CT, Symbia Intevo, Siemens Healthineers, RSNA 2016
News | SPECT Imaging | December 06, 2016
December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
prostate cancer, PET imaging, Johns Hopkins, Daniel Thorek, 11B6 antibody

Uptake of 89Zr-11B6 in the prostate of a transgenic mouse with prostate cancer. Image courtesy of Daniel Thorek

News | Prostate Cancer | November 30, 2016
An international group of researchers report success in mice of a method of using positron emission tomography (PET)...
Overlay Init